ArticleCancer epidemiology2022
Ovarian cancer survival by stage, histotype, and pre-diagnostic lifestyle factors, in the prospective UK Million Women Study.
Article in Cancer epidemiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 90 citations in OpenAlex.
- Combination of transvaginal ultrasound with cervical cancer screening contributes to early detection of ovarian cancer: Clinical trial.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026Trial
- Clinical Value of an LDH-CA125-NLR Panel for Diagnosis, Platinum Resistance, and Prognostic Assessment in Epithelial Ovarian Cancer.Current oncology (Toronto, Ont.) · 2026Article
- Blood Plasma Analysis in Ovarian Cancer Patients Using an AFM/MS Approach: Effect of Sample Dilution on Proteome Depth.International journal of molecular sciences · 2026Article
- Fagotti Score (FS) Compared with Peritoneal Cancer Index (PCI) for Preoperative Assessment of Optimal Cytoreduction in Upfront Laparoscopy.Current oncology (Toronto, Ont.) · 2026Article
- Comprehensive assessment of incidence, mortality, and lifetime risk of ovarian cancer: a global study with forecasts to 2050.Journal of gynecologic oncology · 2026Article
- Preoperative hypoalbuminemia and survival among patients selected for primary cytoreduction in advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study.Gynecologic oncology · 2026Article
- Safety, Tolerability, and Pharmacokinetics of Mirvetuximab Soravtansine in Chinese Patients With Folate Receptor α-Positive Advanced Ovarian Cancer.Cancer medicine · 2026Article
- Prevalence of ovarian cancer cachexia in patients undergoing cytoreductive surgery at the University of Colorado between 2014-2024.Journal of ovarian research · 2026Article
- A Cost Consequence Analysis of Seven Diagnostic Strategies for Ovarian Cancer: A Model-Based Economic Evaluation.BJOG : an international journal of obstetrics and gynaecology · 2026Article
- Structure-Activity Relationships of Silver(I)- and Gold(I)-NHC Complexes Reveal Distinctly Different Responses of Cisplatin-Resistant Ovarian Cancer to Bis-NHC-Gold(I) Derivatives.Journal of medicinal chemistry · 2026Article
- FOXA1 in Ovarian Cancer: A Potential Therapeutic Target to Enhance Immunotherapy Efficacy.International journal of molecular sciences · 2026Article
- Development of a Prognostic Nomogram in Epithelial Ovarian Cancer Based on KELIM: A Retrospective Study at TuDu Hospital, Vietnam.Diagnostics (Basel, Switzerland) · 2026Article
- Molecular Signature of Cisplatin Resistance in Ovarian Cancer Identifies Therapeutic Opportunities for Re-sensitization.Journal of Cancer · 2026Article
- Global, regional, and national burden of ovarian cancer due to high BMI, 1990-2021 and projections to 2050: a systematic analysis based on the global burden of disease 2021 study.Frontiers in nutrition · 2026Article
- Clinical Implications of Cytology Negative Pleural Effusion in Advanced Stage Epithelial Ovarian Cancer-Insights from a Tertiary Cancer Center in Northeast India.Indian journal of surgical oncology · 2026Article
- Diabetes mellitus and the risk of ovarian cancer: an updated systematic review and meta-analysis of cohort and case-control studies.Diabetology & metabolic syndrome · 2025Review
- Development and validation of a histology-specific natural history model of ovarian cancer.American journal of obstetrics and gynecology · 2025Article
- Genetic variants of LncRNA associated with splicing regulation and their impact on ovarian cancer development.Functional & integrative genomics · 2025Article
- Homologous Recombination Proficiency in High-Grade Serous Epithelial Ovarian Cancer Tumors: The Dark Side of the Moon.Current issues in molecular biology · 2025Review
- Growth kinetics of high-grade serous ovarian cancer: implications for early detection.British journal of cancer · 2025Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
backgroundOvarian cancer is the fifth leading cause of cancer mortality in UK women. Ovarian cancer survival varies by disease stage at diagnosis, but evidence is mixed on the effect of tumour histological type (histotype) and other factors.
methods1.3 million UK women completed a detailed health questionnaire in 1996-2001 and were followed for incident cancers and deaths via linkage to national databases. Using Cox regression models, we estimated adjusted relative risks (RRs) of death from ovarian cancer, by stage at diagnosis, tumour histotype, and 16 other personal characteristics of the women.
resultsDuring 17.7 years' average follow-up, 13,222 women were diagnosed with ovarian cancer, and 8697 of them died from the disease. Stage at diagnosis was a major determinant of survival (stage IV vs I, RR=10.54, 95% CI: 9.16-12.13). Histotype remained a significant predictor after adjustment for stage and other factors, but associations varied over the follow-up period. Histotype-specific survival was worse for high-grade than low-grade tumours. Survival appeared worse with older age at diagnosis (per 5 years: RR=1.19, 95% CI: 1.15-1.22), higher BMI (per 5-unit increase: RR=1.06, 95% CI: 1.02-1.11), and smoking (current vs never: RR=1.17, 95% CI: 1.07-1.27), but there was little association with 13 other pre-diagnostic reproductive, anthropometric, and lifestyle factors.
conclusionStage at diagnosis is a strong predictor of ovarian cancer survival, but tumour histotype and grade remain predictors of survival even after adjustment for stage and other factors, contributing further evidence of biological dissimilarity between the ovarian cancer histotypes. Obesity and smoking represent potentially-modifiable determinants of survival, but the stronger association with stage suggests that improving earlier diagnosis would have a greater impact on increasing ovarian cancer survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.